FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

NPS Pharmaceuticals news from FierceBiotech

News

GSK ends NPS's osteoporosis drug study

Bad news for NPS Pharmaceuticals: the company announced late Thursday that its partner GlaxoSmithKline would abandon a Phase II study of Ronacalaret, an osteoporosis drug. According to SEC filings... Read more...

C&L: Milano tapped to run ViroPharma

ViroPharma has named Vincent Milano to succeed Michel de Rosen as president and chief executive. De Rosen will continue as non-executive chairman. Also, Daniel Soland has been named COO. NPS... Read more...

ALSO NOTED: Acorda shares bounce on new data; Endo CEO hits the exit door; BioSante in protocol deal; and much more...

> Shares of Acorda Therapeutics took a big bounce yesterday when the company announced new data demonstrating that its multiple sclerosis drug Fampridine-SR does not raise heart-related risks... Read more...

ALSO NOTED: More takeover targets for Big Pharma; Byetta trial delivers positive data; and much more...

> Industry watchers can't resist identifying takeover targets for Big Pharma. This week, the Motley Fool's radar is picking up Sepracor--which announced layoffs yesterday after a few tough... Read more...

NPS pockets $30M, parts ways with AstraZeneca

NPS Pharmaceuticals and AstraZeneca are ending their six-year-old collaboration to develop new drugs for metabotropic glutamate receptors, or mGluRs. AstraZeneca is paying NPS $30 million for the... Read more...

Press Releases

PRESS RELEASE: NPS Pharmaceuticals Says CFO to Leave, Replacement Named

NPS Pharmaceuticals Says CFO to Leave, Replacement Named BEDMINSTER, N.J., Nov. 13 -- NPS Pharmaceuticals announced today the promotion of Andrew Rackear to senior vice president, legal affairs, and Read more >>

PRESS RELEASE: Nycomed Confirms Commitment to GATTEX Partnership; NPS to Receive $25 Million Payment

Nycomed Confirms Commitment to GATTEX Partnership; NPS to Receive $25 Million Payment BEDMINSTER, N.J., Oct. 31 -- NPS Pharmaceuticals, Inc. announced today that Nycomed, after an in-depth review of Read more >>

PRESS RELEASE: NPS Pharmaceuticals PREOS Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism

NPS Pharmaceuticals PREOS Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism PARSIPPANY, N.J., Sept. 19 -- NPS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Read more >>